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Abstract
Background and Aim: Intraoperative blood loss is a frequent complication of hepatic resection and orthotopic liver
transplantation. Recombinant activated coagulation factor VII (rFVIIa) is a coagulation protein that induces hemostasis by
directly activating factor X. There is no clear information about the prophylactic value of rFVIIa in hepatobiliary surgery,
specifically in liver resection and orthotopic liver transplantation. The aim of this study was to assess the effect of rFVIIa
prophylaxis to prevent mortality and bleeding resulting from hepatobiliary surgery.
Methods: Relevant randomized trials were identified by searching The Cochrane Central Register of Controlled Trials in The
Cochrane Library, MEDLINE, EMBASE, and Science Citation Index. Randomized clinical trials comparing different rFVIIa prophylactic
schemas against placebo or no intervention to prevent bleeding in hepatobiliary surgery were included. Adults undergoing liver
resection, partial hepatectomy, or orthotopic liver transplantation were included. Dichotomous data were analyzed calculating odds
ratios (ORs) and 95% confidence intervals (CIs). Continuous data were analyzed calculating mean differences (MD) and 95% CIs.
Results: Four randomized controlled trials were included. There were no significant differences between rFVIIa and placebo
for mortality (OR 0.96; 95% CI 0.35–2.62), red blood cell units (MD 0.32; 95% CI 20.08–0.72) or adverse events (OR 1.55; 95%
CI 0.97–2.49).
Conclusions: The available information is limited, precluding the ability to draw conclusions regarding bleeding prophylaxis
in hepatobiliary surgery using rFVIIa. Although an apparent lack of effect was observed in all outcomes studied, further
research is needed.
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Introduction
Hepatic resection is often accompanied by intraoperative blood
loss occurring during parenchyma transection or tumor resection.
Similarly, orthotopic liver transplantation (OLT) may also cause
excessive blood loss during surgery, which may lead to increased
postoperative morbidity and mortality [1]. Many surgical tech-
niques to achieve vascular control during hepatic resection have
been proposed, producing good results [2]. Recently, pharmaco-
logical approaches have been used to induce a primary hemostatic
effect in an attempt to reduce intraoperative blood loss [3].
Recombinant activated coagulation factor VII (rFVIIa) (Novo-
Seven, Novo Nordisk, Denmark) is a coagulation protein that
induces hemostasis through direct activation of factor X, starting
the conversion of prothrombin to thrombin to form a hemostatic
clot. At the site of vascular injury, rFVIIa binds to the surface of
activated platelets, increasing localized thrombin generation [4].
Use of rFVIIa has been approved for the treatment of bleeding in
patients with hemophilia A and B, acquired hemophilia, factor VII
deficiency, or Glanzmann thrombasthenia refractory to platelet
administration. It has also been used to manage hemorrhage
caused by severe traumatic injury or transplantation, cardiac
surgery, treatment of intracerebral hemorrhage, and bleeding
associated with anticoagulation therapy [5,6].
No clear information exists regarding the use of rFVIIa to prevent
bleeding in hepatobiliary surgery. The present study aimed to assess
the effect of prophylactic rFVIIa in preventing bleeding and reducing
mortality in patients undergoing partial hepatectomy or OLT.
Methods
Types of Studies
Randomized clinical trials that compared different rFVIIa
prophylactic schedules and dosages against placebo or no
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22581intervention to prevent bleeding in hepatobiliary surgery were
included. These trials were included irrespective of publication
status, language, and blinding.
Types of Participants
Patients were included if they were 18 years or older and had
undergone liver resection, partial hepatectomy, or OLT, irrespec-
tive of the indication for the surgical procedure and liver
functional status assessed by any scale. Patients with recent
abdominal surgery or bleeding disorders and those scheduled for
multiorgan transplantation were excluded.
Types of Interventions
The following interventions were considered:
– use, dosage, benefits, and harms of prophylactic rFVIIa in
OLT;
– use, dosage, benefits, and harms of prophylactic rFVIIa in liver
resection.
Control groups received placebo or no intervention.
Types of Outcome Measures
The primary outcome measures were:
– mortality rate;
– transfusion requirements;
– adverse events, which included:
& any serious adverse events that were fatal, life threatening,
or requiring inpatient hospitalization or prolongation of
existing hospitalization;
& any adverse events that resulted in significant disability or
incapacity;
& any important medical events that might not be immedi-
ately life threatening or that resulted in death or
hospitalization, but might jeopardize the patient or require
intervention to prevent one of the above outcomes;
& any adverse events that required discontinuation of
medication;
& thromboembolic events.
The secondary outcome measures were:
– reduction of bleeding complications assessed by any scale;
– improvement in coagulation status assessed by any scale;
– recurrence of bleeding after the surgery;
– bleeding during the surgery;
– length of hospitalization.
Search Methods to Identify Studies
Electronic searches. Relevant randomized trials were
identified by searching The Cochrane Central Register of
Controlled Trials (CENTRAL) in The Cochrane Library,
MEDLINE, EMBASE, and Science Citation Index, following a
structured strategy (see search strategy in Table S1).
Searching Other Resources
The references of all identified studies were inspected for more
trials.
Selection of Studies
Two authors independently inspected each identified reference
and applied the inclusion criteria. For potentially relevant articles
or in cases of disagreement between the two reviewers, the full-text
article was obtained and inspected independently. If the dis-
agreement could not be resolved by discussion, a third reviewer
appraised the article to resolve the disagreement. Justification for
exclusion of each study was documented.
Data Extraction and Management
Two authors independently extracted the data from the
included trials. In case of disagreement, a third author extracted
the data. The extracted data were discussed and decisions were
documented; when necessary, the authors of the original studies
were contacted for clarification. Justification for exclusion of each
study was recorded. Trials were identified using the last name of
the first author and the year in which the trial was published, and
these were organized chronologically.
Characteristics of Studies
The following characteristics of the studies were recorded:
– date, location, and setting;
– publication status;
– case definitions used;
– sponsor of trial.
Characteristics of Participants
The following characteristics of the participants were recorded:
– total number of participants;
– age, sex, and nationality;
– severity of liver disease (by biochemical or radiological data),
regardless of the criteria used;
– previous treatment with rFVIIa and recent surgical interven-
tions.
Characteristics of Interventions
The following characteristics of the interventions were recorded:
– usage of prophylactic rFVIIa: dose, mode of administration,
schedule, and length of follow-up (months);
– characteristics of hepatic resection, liver transplantation, and
indications;
– other interventions to prevent bleeding.
Assessment of Risk of Bias in Included Studies
Two authors independently assessed the bias risk of the trials
without masking the trial names. For this purpose, instructions
given in the Cochrane Handbook for Systematic Reviews of
Interventions [7] were followed.
Measures of Treatment Effect and Data Analysis
RevMan Analyses (The Nordic Cochrane Centre, Copenhagen,
Denmark) was used to analyze the data. Dichotomous data were
analyzed by calculating odds ratios (ORs) and 95% confidence
intervals (CIs). Continuous data were analyzed calculating mean
differences (MDs) and 95% CIs between intervention groups in
each trial. Interventions were compared and stratified by the type
of surgical procedure (liver resection or OLT).
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harmonized across studies by estimating the means and standard
deviations from the reported medians and ranges according to the
method of Pudar Hozo et al. [8]. After harmonization, the MDs
were calculated between intervention groups.
Assessment of Heterogeneity
We checked the heterogeneity of effects across trials by visual
inspection of the forest plots and x
2 and I
2 tests for heterogeneity
[7]. Statistical heterogeneity was defined as P.0.10 (x
2)o r
I
2.25%. Potential sources of heterogeneity were assessed by
stratification, mainly, type of surgical procedure (liver resection or
OLT) and high and low rFVIIa doses.
Sensitivity Analysis
We analyzed the data using both fixed- and random-effects
models. When both models produced similar estimates, the fixed-
effect result was reported. Outcomes were analyzed as reported in
the trial; that is, either per protocol or as intention-to-treat
analysis.
Assessment of Reporting Biases
A funnel plot estimating the precision of trials (plot of the
logarithm of the relative risk against the sample size) was used to
detect publication bias. In addition, the standard normal deviate
(SND), defined as the relative risk divided by its standard error,
was regressed against the estimate’s precision (regression equation:
SND=a+b6precision) to facilitate the prediction of potential
heterogeneity or data irregularities in the meta-analyses [9]. In this
equation, the SND reflects the degree of funnel plot asymmetry as
measured by the intercept from the regression analysis.
Results
Study Selection
A total of 74 potential references were retrieved and screened:
31 were narrative reviews or letters to the editor, 28 were
nonrandomized studies, 10 were systematic reviews or meta-
analyses of different target trials, and one was a clinical guideline.
Finally, four randomized controlled trials were included in the
analysis (Figure 1).
Study Characteristics
We included four randomized controlled trials designed to
evaluate rFVIIa prophylaxis in liver surgery. The number of
patients included in the trials who underwent partial hepatectomy
[3,10] or OLT [4,11] ranged from 83 to 221. The countries
involved were Spain, Germany, France, United Kingdom, China,
Taiwan, and Thailand. All but one trial involved cirrhotic patients
[3]. The doses of rFVIIa ranged from 20 to 120 mg/kg; although
different, all rFVIIa prophylactic schemes were compared against
placebo. In the study by Lodge et al. [3], a presurgical dose was
used and another dose was administered if surgery lasted more
than 6 hours. In the studies by Shao et al. [10] and Lodge et al.
[11], a presurgical dose was used with additional doses every
2 hours. In the study by Planinsic et al. [4], a single presurgical
dose was used. The study by Shao et al. [10] evaluated the efficacy
of rFVIIa in reducing red blood cell transfusions in patients
undergoing partial hepatectomy. Lodge et al. [3] evaluated the
hemostatic effect and safety of rFVIIa in patients receiving a major
partial hepatectomy. Planinsic [4] and Lodge et al. [11] evaluated
the efficacy and safety of rFVIIa in reducing bleeding and
transfusion requirements in patients receiving OLT. All studies
were randomized, double-blind, placebo-controlled trials (Table 1).
Risk of Bias within Studies
All trials included were at risk of bias. Sequence generation and
allocation concealment were not described properly and remained
unclear for evaluation purposes. Another important source of bias
was sponsorship because all studies were sponsored by the
pharmaceutical industry (Table 2).
Figure 1. Flow diagram for trial selection.
doi:10.1371/journal.pone.0022581.g001
Table 1. Characteristics of the included studies.
Lodge 2005a Shao 2006 Lodge 2005 Planinsic 2005
Population (patients) 185 (PH) 221 (PH) 182 (OLT) 83 (OLT)
Intervention rFVIIa 20, 80 mg/Kg rFVIIa 50, 100 mg/Kg rFVIIa 60, 120 mg/Kg rFVIIa 20, 40, 80 mg/Kg
Comparison Placebo Placebo Placebo Placebo
Outcome Haemostatic effect
and safety of rFVIIa
Efficacy of rFVIIa in
reducing blood
transfusions
Efficacy and safety of rFVIIa
in reducing transfusion
requirements
Efficacy and safety of
rFVIIa in the reduction
of bleeding in OLT
Study Randomized, double blind,
placebo controlled trial
Randomized, double blind,
placebo controlled trial
Randomized, double blind,
placebo controlled trial
Randomized, double blind,
placebo controlled trial
PH: Partial hepatectomy; OLT: Orthotopic liver transplant; rFVIIa: Recombinant activated coagulation factor VII.
doi:10.1371/journal.pone.0022581.t001
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Mortality. The four trials included assessed mortality and
involved 671 subjects. The mortality rate did not differ
significantly (OR 0.96; 95% CI 0.35–2.63). There were also no
significant differences in mortality stratified according to the type
of surgery into liver transplantation (OR, 1.35; 95% CI 0.27–6.72)
compared with liver resection (OR 0.77; 95% CI 0.21–2.80)
(Figure 2) or according to rFVIIa dose of #40 mg/kg (OR 1.36;
95% CI 0.38–4.93) compared with .40 mg/kg (OR 0.67; 95% CI
0.21–2.13) (data not shown).
Red blood cells requirement. In the trial by Lodge et al.
[11], the requirement for red blood cells was reduced from 8.2
units in the placebo group to 7 units in the 60 mg/kg rFVIIa group
and to 6.3 units in the 120 mg/kg group (Table 3). However, no
differences in the requirement for red blood cells were observed in
the other studies. Overall, the data did not show significant
benefits in terms of the mean number of blood cell units transfused
(MD 0.32; 95% CI 20.08–0.72 units), although a marginal effect
was observed in the lower dose groups (MD 0.61; 95% CI 0.02–
1.20 units) (Figure 3).
Serious adverse events. The overall rate of serious adverse
events did not differ significantly (OR 1.55; 95% CI 0.97–2.49).
There were no differences in the sensitivity analysis between
surgical procedures of liver transplantation (OR 1.82; 95% CI,
0.99–3.35) compared with liver resection (OR 1.21; 95% CI 0.57–
2.56) (Figure 4), or according to the dose of rFVIIa#40 mg/kg
(OR 1.27; 95% CI 0.61–2.64) compared with .40 mg/kg (OR
1.29; 95% CI 0.77–2.16) (data not shown).
Thromboembolic events. The rate of thromboembolic
events did not differ significantly (OR 1.37; 95% CI 0.68–2.77).
Sensitivity analysis did not show differences in thrombolytic events
between liver transplantation (OR 1.41; 95% CI 0.61–3.29) and
liver resection (OR 1.28; 95% CI 0.36–4.53) (Figure 5), or between
rFVIIa dose #40 mg/kg (OR 0.85; 95% CI 0.25–2.94) and
.40 mg/kg (OR 1.37; 95% CI 0.68–2.77) (data not shown). The
thromboembolic events reported were acute myocardial infarction
in three trials (four cases in the rFVIIa group [3,12,13]), portal
vein thrombosis in two trials (one patient in the placebo [3] and
one in the rFVIIa group [13]), and pulmonary embolism in two
trials (two patients in the rFVIIa group [3] and one in the placebo
Table 2. Risk of bias assessment of the included trials.
Source of bias Lodge 2005 Lodge 2005a Planinsic 2005 Shao 2006
Sequence Generation Unclear Low risk of bias Low risk of bias Unclear
Allocation concealment and blinding Unclear Low risk of bias Unclear Unclear
Incomplete outcome data Low risk of bias Low risk of bias Low risk of bias Low risk of bias
Selective outcome reporting Low risk of bias Low risk of bias Low risk of bias Low risk of bias
Other sources of Bias* High risk of bias High risk of bias High risk of bias High risk of bias
*The other source of bias in all trial was the source of the financial support (industry).
doi:10.1371/journal.pone.0022581.t002
Figure 2. Meta-analysis plot for mortality after liver resection and liver transplantation. There were no differences overall or according to
the type of hepatobiliary surgery.
doi:10.1371/journal.pone.0022581.g002
Activated rFVIIa in Hepatic Surgery
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22581group [13]). Other thromboembolic events were suspected to be
mesenteric vein thrombosis [13], arterial thrombosis, and
thrombophlebitis [12].
Secondary outcomes. There was great heterogeneity regarding
secondary outcomes. Lodge et al. did not observe differences in the
duration of hospitalization between groups (17, 19, and 22 days for
placebo, 60 mg/kg, and 120 mg/kg, respectively) [11]. Shao et al. found
no changes in the surgical time from rFVIIa prophylaxis (152, 167, and
144 minutes for placebo, 50 mg/kg, and 100 mg/kg, respectively).
Lodge et al. [3] found similar results (4.06, 4.04, and 3.61 hours for
placebo, 20 mg/kg, and 50 mg/kg, respectively). Lodge et al. [3] found
no reduction in bleeding during surgery (1422, 1372, and 1073 ml for
placebo, 20 mg/kg, and 50 mg/kg, respectively).
Discussion
FVIIa was developed in 1985 and was introduced to treat
patients with hemophilia in 1989 [14]. Good outcomes were
observed in these patients, which led to the promotion of
rFVIIa use in other settings. There is some evidence about the
safety and efficacy of rFVIIa for controlling hemorrhage in
patients without hemophilia, mainly in pediatric populations
[15]. In adults, hemorrhagic obstetric complications can be
reduced by rFVIIa [16], and patients with acute intracerebral
hemorrhage may also benefit from the treatment [17]. In
patients with trauma and coagulopathy, rFVIIa reduces fresh-
frozen plasma transfusions, multiorgan failure, and acute
respiratory distress syndrome [18]. Prophylactic use of rFVIIa
has been tested in other surgical fields, and several randomized
clinical trials have suggested that its use reduces the number of
required blood cell transfusions without significantly affecting
mortality [19,20,21].
In the field of liver diseases, in which impaired coagulation is
almost the rule [22], rFVIIa might provide an adequate approach
for preventing bleeding complications. The most important
surgical procedures in these patients are liver transplantation
and liver resection. Noncontrolled studies suggested that rFVIIa
significantly reduces mortality [23,24] without increasing serious
adverse events [25]. However, to our knowledge, no systematic
review or meta-analysis has assessed the role of rFVIIa in bleeding
prophylaxis in liver transplantation or liver resection.
Table 3. Secondary outcomes assessed in the included trials.
Units
of FFP
(median)
Units
of RBC
(median)
Hospitalization
length (days)
(average)
Lodge 2005
Placebo 11 8.2 17
60 mg/Kg 9.4 7 19
120 mg/Kg 11.9 6.3 22
Planinsic 2005
Placebo 11 8
20 mg/Kg 8.5 8.5
40 mg/Kg 15.5 13
80 mg/Kg 6 7
Lodge 2005a
Placebo 7
20 mg/Kg 7
80 mg/Kg 7
Shao 2006
Placebo 0 0
50 mg/Kg 0 0
100 mg/Kg 0 0
doi:10.1371/journal.pone.0022581.t003
Figure 3. Meta-analysis plot for the number of blood cell units transfused according to the rFVIIa dose. The dose was classified as lower
or higher. Slightly more units were transfused in the low-dose rFVIIa group compared to the placebo group (marginal effect).
doi:10.1371/journal.pone.0022581.g003
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trials, three of them in patients with cirrhosis. Use of prophylactic
rFVIIa did not significantly modify the rates of mortality and
serious adverse events. Prophylactic rVIIa failed to show a
consistent improvement in proximal benefit indicators, such as
the number of blood transfusions, although a marginal reduction
Figure 4. Meta-analysis plot for serious adverse events in liver resection and liver transplantation. There were no differences for liver
resection and overall, but a trend towards an increasing serious adverse event rate was observed in the liver transplantation group.
doi:10.1371/journal.pone.0022581.g004
Figure 5. Meta-analysis plot for thromboembolic events in liver resection and liver transplantation. There were no differences overall or
by type of hepatobiliary surgery.
doi:10.1371/journal.pone.0022581.g005
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trend towards more serious adverse events among patients
undergoing liver transplantation who were treated with rFVIIa
was observed. The intervention did not increase the risk for
thromboembolic events. An increased risk has been reported
elsewhere, although this observation could reflect the specific
characteristic of the clinical setting [17,26].
The present meta-analysis included studies of the effectiveness
of prophylactic rVIIa given to patients undergoing either hepatic
transplantation or liver resection. Transplantation patients are at
increased risk of mortality and morbidity because of immunosup-
pression or graft rejection. However, these procedures share
hepatic resection and large bleeding as a common characteristic,
suggesting that they might also benefit from prophylactic rFVIIa.
We observed a homogeneous lack of effect of rFVIIa prophylaxis
in either surgical group for all outcomes studied.
The present meta-analysis is limited by the small number of
trials included, precluding any definite conclusions about the value
of the prophylactic use of rFVIIa in hepatobiliary surgery. Red
blood cells requirement was the primary outcome in all studies
included, under the expectation that this indicator would be
heavily influenced by prophylactic rFVIIa. However, differences
in the reporting of transfused blood units precluded a direct
comparison between studies. A mathematical transformation was
used to generate a global estimate of the effect of rFVIIa over the
adjusted number of transfused blood units; while scientifically
sound, this transformation may not necessarily reflect the real
effect accurately. Fortunately, all studies provided comparable
mortality data, allowing a fair comparison of this more distal but
important outcome. Such an approach assumes that a reduction in
mortality should reflect an improvement of intermediate variables.
We did not observe such association. Still, readers should exert
caution while interpreting mortality results, since the original
studies were not powered to specifically evaluate this outcome.
Considering all available evidence together, prophylactic
rFVIIa failed to significantly modify any of the outcomes studied.
This has implications for clinical practice because there appears to
be no clear evidence to promote its use in OLT or liver resection.
In addition, no high-quality trials have been published since 2006,
and no additional trials have been registered in ClinicalTrials.gov.
More trials are needed to adequately evaluate the use of
prophylactic rFVIIa in liver resection and transplantation.
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